← Leaderboards
Dave S B Hoon
John Wayne Cancer Institute
$13,127,002
Attributed
$13,127,002
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$13,127,002 · 11
By mechanism
P01$7,531,636 · 7
R01$3,801,284 · 2
R33$1,605,282 · 1
R21$188,800 · 1
Top collaborators
No co-investigators on record.
Most similar at John Wayne Cancer Institute
Same institution · by research overlap
- Donald L Morton$20,085,525
- Robert M Elashoff$19,731,308
- Alistair J Cochran$1,667,088
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaSpecimenNeoplasm MetastasisParaffin EmbeddingTissuesGenomicsLymph NodesStagingFollow-UpTumorSiteMolecularBiological MarkersEpigenomicsClinical TrialsMetastatic MelanomaRecurrenceMethylationCutaneous MelanomaGenesBloodPolymerase Chain ReactionDisease OutcomeResources
Grant awards (31)
Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment$382,423
R01 · FY2017 · CA · contact PI
Identification of Melanoma Brain Metastasis Tumor Biomarkers$382,423
R01 · FY2017 · CA · contact PI
Identification of Melanoma Brain Metastasis Tumor Biomarkers$382,423
R01 · FY2016 · CA · contact PI
Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment$382,423
R01 · FY2016 · CA · contact PI
Identification of Melanoma Brain Metastasis Tumor Biomarkers$382,423
R01 · FY2015 · CA · contact PI
Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment$382,423
R01 · FY2015 · CA · contact PI
Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment$370,950
R01 · FY2014 · CA · contact PI
Identification of Melanoma Brain Metastasis Tumor Biomarkers$370,950
R01 · FY2014 · CA · contact PI
Molecular Diagnostics And Support$707,176
P01 · FY2013 · CA · contact PI
Molecular Analysis of Melanoma Metastasis and Blood in Patients Undergoing Sentin$653,179
P01 · FY2013 · CA · contact PI
Identification of Melanoma Brain Metastasis Tumor Biomarkers$382,423
R01 · FY2013 · CA · contact PI
Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment$382,423
R01 · FY2013 · CA · contact PI
Molecular Diagnostics And Support$762,172
P01 · FY2012 · CA · contact PI
Molecular Analysis of Melanoma Metastasis and Blood in Patients Undergoing Sentin$706,707
P01 · FY2012 · CA · contact PI
Molecular Diagnostics And Support$803,314
P01 · FY2011 · CA · contact PI
Molecular Analysis of Melanoma Metastasis and Blood in Patients Undergoing Sentin$726,293
P01 · FY2011 · CA · contact PI
DNA Markers As Surrogates:Melanoma Patient Response$410,895
R33 · FY2008 · CA · contact PI
Core D: Molecular Diagnostics$210,323
P01 · FY2008 · CA · contact PI
Project 2: Molecular Approaches for Assessing Metastasis and Disease Relapse$160,797
P01 · FY2008 · CA · contact PI
DNA Markers As Surrogates:Melanoma Patient Response$398,931
R33 · FY2007 · CA · contact PI
DNA Markers As Surrogates:Melanoma Patient Response$398,878
R33 · FY2006 · CA · contact PI
DNA Markers As Surrogates:Melanoma Patient Response$396,578
R33 · FY2005 · CA
DNA Markers As Surrogates:Melanoma Patient Response$188,800
R21 · FY2003 · CA
ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS$78,870
P01 · FY2002 · CA
PROGNOSTIC MARKERS FOR ASSESSMENT OF TREATMENT EFFICACY OF MELANOMA$53,375
P01 · FY2002 · CA
CORE--MOLECULAR ONCOLOGY FACILITY$0
P01 · FY2002 · CA
ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS$794,109
P01 · FY2001 · CA
MARKERS TO IMPROVE ASSESSMENT OF TREATMENT EFFICACY FOR METASTATIC MELANOMA$53,375
P01 · FY2001 · CA
ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS$0
P01 · FY2001 · CA
MARKERS TO IMPROVE ASSESSMENT OF TREATMENT EFFICACY FOR METASTATIC MELANOMA$1,027,837
P01 · FY2000 · CA
ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS$794,109
P01 · FY2000 · CA